Board Restructuring at Genmab A/S and Allocation of Restricted Stock Units and Employee Warrants
Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of…
Biogen to Showcase Late-Breaking Phase 2 AMETHYST Data for Litifilimab in Cutaneous Lupus Erythematosus at AAD 2026
Biogen to Showcase Late-Breaking Phase 2 AMETHYST Data on Litifilimab in Cutaneous Lupus Erythematosus at the 2026 American Academy of Dermatology Annual Meeting Biogen Inc. has announced a series of…
TALZENNA Combination with XTANDI Demonstrates Significant Improvement in Radiographic Progression-Free Survival in Metastatic Prostate Cancer
TALZENNA in Combination with XTANDI Shows Marked Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Prostate Cancer Pfizer Inc. has announced compelling topline results from its Phase 3 TALAPRO-3…
Allergan Aesthetics Unveils New Global Insights and Educational Innovations to Advance Modern Aesthetic Treatments
Allergan Aesthetics Highlights Shifting Trends in Modern Aesthetic Care Through Global Survey and Enhanced Educational Initiatives Allergan Aesthetics, a division of AbbVie and a globally recognized leader in the field…
Novo Nordisk Secures U.S. Approval for Wegovy HD (7.2 mg), Delivering 20.7% Average Weight Reduction
Novo Nordisk A/S: Wegovy® HD (7.2 mg) gains US approval, delivering 20.7% average weight reduction Novo Nordisk has reached another major milestone in the treatment of obesity, announcing that the…
Royalty Pharma Strengthens Executive Leadership Team with Strategic Expansion
Royalty Pharma Strengthens Executive Leadership Team to Support Strategic Growth and Investment Expansion Royalty Pharma plc has announced a significant expansion of its senior leadership team, underscoring the company’s continued…
Celltrion Announces U.S. Launch of AVTOZMA Subcutaneous Formulation
Celltrion Launches AVTOZMA® (tocilizumab-anoh) Subcutaneous Formulation in the U.S. Market Celltrion has announced a significant milestone in its ongoing efforts to expand access to biologic therapies in the United States,…
Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients
Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus…
Pfizer Reports Positive Phase 2 Topline Results for Atirmociclib, a Next-Generation CDK4 Inhibitor, in Second-Line Metastatic Breast Cancer
Pfizer reports positive Phase 2 topline results for next-generation CDK4 inhibitor atirmociclib in second-line metastatic breast cancer Pfizer Inc. today announced positive topline results from the randomized Phase 2 FOURLIGHT-1…
Allergan Aesthetics Introduces Skin Quality Index to Transform Skin Health Communication
Allergan Aesthetics Introduces New Skin Quality Index to Transform How Skin Health Is Measured and Communicated Allergan Aesthetics, an AbbVie company, today announced the launch of the Skin Quality Index…
ICON plc Announces Timing Update for Q4 and Full-Year 2025 Earnings and Accounting Investigation
ICON plc announces revised timeline for Q4 and full-year 2025 earnings as investigation into accounting practices continues. ICON plc, today announced that it intends to release its fourth quarter and full…
GSK’s Arexvy RSV Vaccine Gains U.S. Approval for At-Risk Adults Aged 18–49
FDA Expands Approval of GSK’s RSV Vaccine Arexvy to Include At-Risk Adults Aged 18–49 GSK plc today announced that the US Food and Drug Administration (FDA) has expanded the approved…